Skip to main content
Mereo BioPharma Group plc logo

Mereo BioPharma Group plc — Investor Relations & Filings

Ticker · MREO ISIN · GB00BZ4G2K23 LEI · 213800U8JQHIJOS5AS09 US Manufacturing
Open in API
Filings indexed 635 across all filing types
Latest filing 2020-02-12 Regulatory Filings
Country GB United Kingdom
Listing US MREO

About Mereo BioPharma Group plc

https://www.mereobiopharma.com/

Mereo BioPharma Group plc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare diseases with limited or no treatment options. The company's strategy involves acquiring and advancing promising clinical-stage product candidates that have been de-prioritized by larger pharmaceutical or biotechnology companies. This capital-efficient model allows it to develop a specialized pipeline. Its two lead programs are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat for Alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). Mereo BioPharma also engages in strategic partnerships and out-licenses other clinical assets to deliver impactful treatments to patients.

Recent filings

Filing Released Lang Actions
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer submitted to the SEC under the Securities Exchange Act of 1934. It includes a press release as an exhibit but does not contain detailed financial statements or substantive financial data. The document length is short (1412 characters), and it primarily serves as a regulatory filing to report current information rather than a full financial report or earnings release. According to the rules, Form 6-K filings are best classified under Regulatory Filings (RNS) as they are miscellaneous regulatory announcements that do not fit into other specific categories.
2020-02-12 English
Update on Distribution
Regulatory Filings Classification · 98% confidence The document is an RNS (Regulatory News Service) announcement from Mereo BioPharma regarding a cash distribution to holders of Contingent Value Rights (CVRs) following a licensing agreement. While it discusses financial payments, it is a specific corporate announcement rather than a full financial report, earnings release, or dividend notice. As it is a regulatory announcement provided via the London Stock Exchange's RNS service, it falls under the 'Regulatory Filings' category.
2020-02-12 English
Holding(s) in Company
Major Shareholding Notification Classification · 100% confidence The document is a 'TR-1: Standard form for notification of major holdings', which is a regulatory requirement for disclosing changes in significant share ownership. It explicitly identifies the issuer (Mereo BioPharma Group plc) and the person subject to the notification (Link Fund Solutions Ltd), detailing the percentage of voting rights held. This aligns perfectly with the definition of a Major Shareholding Notification.
2020-02-11 English
Second Price Monitoring Extn
Regulatory Filings Classification · 100% confidence The document is a short notification from the London Stock Exchange's Regulatory News Service (RNS) regarding a 'Second Price Monitoring Extension' for a specific security. It does not contain financial statements, management reports, or corporate governance details, but rather serves as a technical market announcement regarding trading parameters. As it is a regulatory announcement that does not fit into specific categories like M&A or dividends, it falls under the RNS fallback category.
2020-02-10 English
Price Monitoring Extension
Regulatory Filings Classification · 98% confidence The document is a short notification from the London Stock Exchange's Regulatory News Service (RNS) regarding a 'Price Monitoring Extension' for Mereo BioPharma Group plc. It is a standard automated regulatory announcement regarding trading mechanics rather than a financial report, management update, or corporate action. As it does not fit into specific categories like dividends, share issues, or earnings, it falls under the general regulatory filing category.
2020-02-10 English
6-K
Capital/Financing Update Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Mereo BioPharma Group PLC, with the SEC. It includes exhibits related to convertible loan notes, warrant instruments, subordination deeds, amendment letters, securities purchase agreements, registration rights agreements, and a press release. The content focuses on financing agreements and related legal instruments dated February 2020. There is no indication of financial statements or earnings data, nor is it an annual or quarterly report. The presence of loan note instruments, securities purchase agreements, and amendments to loan agreements strongly indicates this is an update on the company's capital or financing activities. The document length is 2576 characters, which is relatively short but contains substantive information about financing arrangements rather than just an announcement. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2020-02-10 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.